Today, we launch Signios Bio, a rebrand of what was previously known as MedGenome US Research Services. With a focus on scientific collaboration and breakthrough discovery, Signios Bio offers an integrated end-to-end suite of multiomic technologies.

Why Signios Bio? The Start of a New Era

The establishment of Signios Bio is a strategic move to address the changing landscape of biomedical research.  While MedGenome US achieved significant progress in genomic research, we recognized the increasing need for our partners to be more aware of the full suite of Signios Bio’s capabilities, including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology—all powered by a proprietary, AI-driven bioinformatics platform. These comprehensive capabilities empower pharmaceutical companies, biotech firms, and academic institutions to decode complex disease biology, identify novel biomarkers, and drive forward targeted therapies and diagnostics.  

Our Mission: Listening to the Signals of Life

The name “Signios” (derived from “signals”) reflects our core mission: to decipher the intricate messages encoded within our biology. We believe that the key to understanding and treating disease lies in integrating data from multiple omics sources—genomics, transcriptomics, proteomics, epigenomics, metabolomics, and microbiomics. By combining these data streams, we gain a holistic, systems-level view of life’s complex processes, revealing insights that would otherwise remain hidden.

Supporting Discovery with AI

At Signios Bio, we use the capabilities of artificial intelligence and machine learning to analyze large datasets, find patterns, identify new drug targets, and develop more precise diagnostics.  Our robust bioinformatics platform enables researchers and clinicians to make data-driven decisions, speeding up the development of new therapies and ultimately improving patient outcomes.

Looking Ahead to Our Goals and Vision

With a team of world-class scientists, bioinformaticians, and engineers, Signios Bio is committed to:

• Accelerating Drug Discovery and Development: We help pharmaceutical and biotech companies identify promising drug candidates, optimize clinical trial design, and bring life-saving therapies to market faster.
• Promoting Inclusivity in Healthcare: By leveraging diverse datasets, we ensure that our research and the resulting therapies benefit all populations, regardless of their genetic background.
• Contributing to a Healthier Global Ecosystem: Our mission of a healthier global population includes supporting precision agriculture research and biodiversity protection through our multiomics and bioinformatics expertise.

Join Us on this Journey

The launch of Signios Bio represents more than just a new name; it’s a renewed commitment to pushing the boundaries of scientific discovery and transforming healthcare. We invite you to join us on this exciting journey as we decode the future of medicine, one signal at a time.

Learn more about our services and explore career opportunities at www.signiosbio.com. Follow us on LinkedIn, Twitter/X, and Bluesky for the latest updates and insights.